AI for Science
Scientific discovery, drug design, materials science, and AI-driven research acceleration. Accelerating humanity's understanding of the world.
Key Benchmarks
Recent Papers
PR3DICTR: A modular AI framework for medical 3D image-based detection and outcome prediction
Daniel C. MacRae, Luuk van der Hoek, Robert van der Wal +5 more
Neuro-Symbolic Activation Discovery: Transferring Mathematical Structures from Physics to Ecology for Parameter-Efficient Neural Networks
Anas Hajbi
WildSci: Advancing Scientific Reasoning from In-the-Wild Literature
Tengxiao Liu, Deepak Nathani, Zekun Li +2 more
The Persona Paradox: Medical Personas as Behavioral Priors in Clinical Language Models
Tassallah Abdullahi, Shrestha Ghosh, Hamish S Fraser +5 more
Naiad: Novel Agentic Intelligent Autonomous System for Inland Water Monitoring
Eirini Baltzi, Tilemachos Moumouris, Athena Psalta +2 more
MedInsightBench: Evaluating Medical Analytics Agents Through Multi-Step Insight Discovery in Multimodal Medical Data
Zhenghao Zhu, Chuxue Cao, Sirui Han +4 more
From Macro to Micro: Benchmarking Microscopic Spatial Intelligence on Molecules via Vision-Language Models
Zongzhao Li, Xiangzhe Kong, Jiahui Su +8 more
Recent Milestones
Anthropic’s $400M Bet on AI Drug Discovery
Anthropic has acquired stealth AI biotech startup Coefficient Bio in an all‑stock deal worth roughly $400 million, pulling a sub‑10‑person team of ex‑Genentech researchers into its healthcare and life sciences unit in early April 2026. The deal, reported by multiple outlets and confirmed by sources close to Anthropic, aims to apply Claude‑style foundation models to end‑to‑end drug discovery workflows.([winbuzzer.com](https://winbuzzer.com/2026/04/05/anthropic-acquires-coefficient-bio-400m-ai-pharma-startup-xcxwbn/))
Anthropic bets $400M on AI drug discovery
On April 4, 2026, multiple outlets reported that Anthropic has acquired New York–based AI biotech startup Coefficient Bio in an all‑stock deal valued at about $400 million. The roughly nine‑person team will join Anthropic’s life sciences unit to build domain‑specific models for drug discovery and biomedical R&D.
Anthropic Buys Coefficient Bio for $400M
Anthropic has acquired New York–based biotech startup Coefficient Bio in a deal valued at about $400 million, mostly in stock. The move, reported on April 3, 2026, folds Coefficient Bio’s biology-focused AI team into Anthropic’s Health Care Life Sciences group to apply Claude models to drug R&D and clinical strategy.
Insilico Opens ‘Science Gym’ for Frontier LLMs
On January 22, 2026, Insilico Medicine announced a new ‘Science MMAI gym’ service designed to train general‑purpose LLMs such as GPT and Qwen to perform better on biology and chemistry tasks. The Hong Kong‑listed biotech says its pipeline can boost model performance by up to 10x on key scientific benchmarks using domain datasets, reward models and reinforcement learning.
GPT‑5.2 helps solve long‑standing Erdős problem
On January 18, 2026, Eclipse founder Neel Somani said he used OpenAI’s GPT‑5.2 Pro to solve Erdős Problem #281, a number theory problem open since 1980. Fields Medalist Terence Tao and other mathematicians reviewed and accepted the proof, and OpenAI president Greg Brockman highlighted the result as a major milestone for AI-assisted science.
Merge Labs raises $250M for brain–AI links
Brain‑computer interface startup Merge Labs emerged from stealth with a reported $252 million seed round, led by OpenAI and other investors. Coverage on January 16 highlights the lab’s plan to build high‑bandwidth, largely noninvasive BCIs that integrate tightly with advanced AI systems.
KAIST AI maps B‑ and T‑cell targets for cancer vaccines
A joint team from KAIST and biotech firm Neogenlogic announced an AI model that predicts which tumor neoantigens will trigger robust B-cell and T-cell responses, enabling personalized cancer vaccine design. The model, validated on large genomic and clinical datasets, is described as the first AI framework to jointly model B-cell immunogenicity and T-cell responses, with clinical trials targeted for 2027.
AI Designs Personalized Cancer Vaccines by 2027
On January 2, 2026, a joint team from KAIST and Korean biotech firm Neogenlogic disclosed an AI platform that predicts both B cell and T cell responses to tumor neoantigens to design personalized cancer vaccines. The group says the framework, detailed in a December 3 Science Advances paper, is the first to jointly model B cell immunogenicity for vaccine design and is being readied for an IND filing with the U.S. FDA targeting clinical trials in 2027.
Nobel Prize for AlphaFold
Demis Hassabis and John Jumper awarded Nobel Prize in Chemistry for AlphaFold.
Nobel Prize for Neural Networks
Geoffrey Hinton and John Hopfield awarded Nobel Prize in Physics for foundational neural network work.
AlphaFold 3 Released
DeepMind releases AlphaFold 3, predicting structures of proteins, DNA, RNA, and small molecules.
AlphaGeometry Solves IMO Problems
DeepMind AlphaGeometry solves International Mathematical Olympiad problems at silver medalist level.
Isomorphic Labs Drug Discovery Partnership
Isomorphic Labs announces major pharmaceutical partnerships worth over $3B.